OS Therapies Inc (OSTX) income statement
OSTXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.80−0.02 (-2.12%)
Close on Nov 20, 2026Market cap $37.04MP/E –Yield –
OS Therapies Inc financial ratios
See a number that looks wrong?
Close on Nov 20, 2026Market cap $37.04MP/E –Yield –
See a number that looks wrong?
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Returns on capital | ||||
| Return on equity | 614.3% | 65.3% | 38.1% | – |
| Return on assets | -464.6% | -280.4% | -976.3% | – |
| Return on tangible assets | 9,129.2% | -280.4% | -986.2% | – |
| Return on capital employed | 1,430.5% | 59.2% | 18.2% | – |
| NOPAT | -$22.68M | -$5.38M | -$3.43M | – |
| Cash flow quality | ||||
| OCF / Net income | 0.50 | 0.82 | 0.39 | – |
| FCF / OCF | 103.3% | – | – | – |
| FCF / Net income | 0.51 | – | – | – |
| FCF / EBITDA | 51.9% | – | – | – |
| Unlevered free cash flow | -$14.70M | – | – | – |
| Levered free cash flow | -$14.70M | – | – | – |
| Efficiency | ||||
| CapEx to OCF | -3.3% | – | – | – |
| CapEx to depreciation | 1.28 | – | – | – |
| Liquidity | ||||
| Current ratio | 0.03 | 1.20 | 0.03 | – |
| Quick ratio | 0.03 | 1.20 | 0.03 | – |
| Cash ratio | 0.02 | 1.20 | 0.00 | – |
| Working capital | -$11.43M | $906.22K | -$23.92M | – |
| Net current asset value | -$11.53M | $806.22K | -$24.02M | – |
| Leverage | ||||
| Assets to equity | -1.12 | -1.70 | -0.03 | – |
| Intangibles to total assets | 95.1% | – | 1.0% | – |
| Interest coverage | ||||
| EBIT / Interest expense | – | -3.32 | -1.26 | – |
| EBITDA / Interest expense | – | -3.32 | – | – |
| Per share | ||||
| EPS (basic) | -0.98 | -1.28 | -1.46 | – |
| EPS (diluted) | -0.98 | -1.28 | -1.46 | – |
| Book value per share | -0.16 | -0.16 | -4.50 | – |
| Tangible book value per share | -0.34 | -0.16 | -4.50 | – |
| Cash per share | 0.0073 | 0.27 | 0.0073 | – |
| Operating cash flow per share | -0.38 | -0.35 | -0.56 | – |
| Free cash flow per share | -0.40 | – | – | – |
| CapEx per share | 0.01 | – | – | – |
| Valuation at period end | ||||
| Market cap | $46.58M | $90.65M | – | – |
| Enterprise value | $44.70M | $88.80M | – | – |
| P/B | -7.6x | -27.8x | – | – |
| P/TBV | -3.7x | -27.8x | – | – |
| P/OCF | -3.3x | -12.4x | – | – |
| EV/OCF | -3.1x | -12.2x | – | – |
| Earnings yield | -61.7% | -9.8% | – | – |
| FCF yield | -31.6% | – | – | – |
| Per employee | ||||
| Total employees | 1,000 | 4 | 4 | 4 |
| Operating profit per employee | -$28.71K | -$1.70M | -$1.09M | – |
| Net income per employee | -$28.75K | -$2.22M | -$1.95M | – |
| Free cash flow per employee | -$14.70K | – | – | – |
| Growth | ||||
| EBIT 1Y growth | -321.3% | -56.9% | – | – |
| EBITDA 1Y growth | -316.1% | – | – | – |
| Net income 1Y growth | -223.7% | -14.0% | – | – |
| Diluted EPS 1Y growth | 23.4% | 12.3% | – | – |
| Operating cash flow 1Y growth | -95.5% | -142.2% | – | – |
| Total assets 1Y growth | 23.5% | 594.0% | – | – |
| Total equity 1Y growth | -86.6% | 86.4% | -36.8% | – |
Every figure here is calculated from standardized financial statements — hover a row name for the formula — not reported by the company. Valuation multiples use the closing price at the end of that period, not today's price.